公开(公告)号：US20220323418A1

公开(公告)日：2022-10-13

申请号：US17662866

申请日：2022-05-11

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Kevin D. G. Pfleger ,  Elizabeth McCall ,  James Williams

IPC: A61K31/4184 ,  A61K31/4178 ,  A61K31/80 ,  A61K45/06 ,  A61K9/00 ,  A61K9/20 ,  A61P13/12 ,  A61P9/06 ,  A61P9/12 ,  A61K31/537 ,  A61K31/28

Abstract: The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.

公开(公告)号：US10525038B2

公开(公告)日：2020-01-07

申请号：US15704713

申请日：2017-09-14

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Kevin D. G. Pfleger ,  Elizabeth McCall ,  James Williams

IPC: A61K31/537 ,  A61K9/00 ,  A61K9/20 ,  A61K31/28 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/80 ,  A61K45/06

Abstract: The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.

公开(公告)号：US20250049840A1

公开(公告)日：2025-02-13

申请号：US18718617

申请日：2022-01-14

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Bronwyn Jane POLLOCK ,  Robert SHEPHERD ,  Nina WEBSTER

IPC: A61K31/80 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48

Abstract: A composition comprising: i. at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof, in particular repagermanium or propagermanium: ii. a diluent in a concentration from 30 to 70% w/w; iii. a binder in a concentration from 2 to 5% w/w: iv. a disintegrant in a concentration from 2 to 8% w/w; and v. a lubricant in a concentration from 0.05 to 5% w/w; and methods of treatment with same.

公开(公告)号：US10058555B2

公开(公告)日：2018-08-28

申请号：US15086823

申请日：2016-03-31

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Kevin D. G. Pfleger ,  Elizabeth McCall ,  James Williams

IPC: A61K31/537 ,  A61K9/00 ,  A61K9/20 ,  A61K31/28 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/80 ,  A61K45/06

CPC classification number: A61K31/4184 ,  A61K9/0019 ,  A61K9/2009 ,  A61K9/2054 ,  A61K31/28 ,  A61K31/4178 ,  A61K31/537 ,  A61K31/80 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.

公开(公告)号：US20240173302A1

公开(公告)日：2024-05-30

申请号：US18282105

申请日：2022-03-18

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Robert Pearson Shepherd ,  Nina Webster

IPC: A61K31/422 ,  A61K31/194 ,  A61K31/4025 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K38/12

CPC classification number: A61K31/422 ,  A61K31/194 ,  A61K31/4025 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K38/12

Abstract: A pharmaceutical composition comprising at least one endothelin A receptor inhibitor or a pharmaceutically acceptable salt thereof and at least one chemokine receptor 2 (CCR2) inhibitor or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240009191A1

公开(公告)日：2024-01-11

申请号：US17675320

申请日：2020-09-18

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Robert Pearson Shepherd ,  Kevin Donald George Pfleger

IPC: A61K31/506 ,  A61K31/4192 ,  A61K31/17 ,  A61K31/341 ,  A61K31/4462 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/4178 ,  A61K31/41 ,  A61P11/00

CPC classification number: A61K31/506 ,  A61K31/4192 ,  A61K31/17 ,  A61K31/341 ,  A61K31/4462 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/4178 ,  A61K31/41 ,  A61P11/00

Abstract: A pharmaceutical formulation comprising at least one angiotensin type 1 receptor (AT1R) blocker and at least one CXC chemokine receptor 2 (CXCR2) pathway inhibitor.

公开(公告)号：US20200046685A1

公开(公告)日：2020-02-13

申请号：US16654912

申请日：2019-10-16

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Kevin D. G. Pfleger ,  Elizabeth McCall ,  James Williams

IPC: A61K31/4184 ,  A61K31/4178 ,  A61K31/80 ,  A61K45/06 ,  A61K9/00 ,  A61K9/20 ,  A61K31/537 ,  A61K31/28 ,  A61P13/12 ,  A61P9/06 ,  A61P9/12

Abstract: The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.

公开(公告)号：US20240366570A1

公开(公告)日：2024-11-07

申请号：US18774024

申请日：2024-07-16

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Kevin D. G. Pfleger ,  Elizabeth McCall ,  James Williams

IPC: A61K31/4184 ,  A61K9/00 ,  A61K9/20 ,  A61K31/28 ,  A61K31/4178 ,  A61K31/537 ,  A61K31/80 ,  A61K45/06 ,  A61P9/06 ,  A61P9/12 ,  A61P13/12

Abstract: The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.

公开(公告)号：US12083102B2

公开(公告)日：2024-09-10

申请号：US17662866

申请日：2022-05-11

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Kevin D. G. Pfleger ,  Elizabeth McCall ,  James Williams

IPC: A61K31/4184 ,  A61K9/00 ,  A61K9/20 ,  A61K31/28 ,  A61K31/4178 ,  A61K31/537 ,  A61K31/80 ,  A61K45/06 ,  A61P9/06 ,  A61P9/12 ,  A61P13/12

CPC classification number: A61K31/4184 ,  A61K9/0019 ,  A61K9/2009 ,  A61K9/2054 ,  A61K31/28 ,  A61K31/4178 ,  A61K31/537 ,  A61K31/80 ,  A61K45/06 ,  A61P9/06 ,  A61P9/12 ,  A61P13/12 ,  A61K31/4178 ,  A61K2300/00 ,  A61K31/80 ,  A61K2300/00 ,  A61K31/537 ,  A61K2300/00

Abstract: The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.

公开(公告)号：US11382896B2

公开(公告)日：2022-07-12

申请号：US16654912

申请日：2019-10-16

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Kevin D. G. Pfleger ,  Elizabeth McCall ,  James Williams

IPC: A61K31/537 ,  A61K9/00 ,  A61K9/20 ,  A61K31/28 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/80 ,  A61K45/06 ,  A61P13/12 ,  A61P9/06 ,  A61P9/12

Abstract: The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.